Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech is well-positioned for long-term success due to multiple factors, including strong clinical data from ongoing trials such as the DURIPANC study in combination with AstraZeneca's Imfinzi, a focus on pancreatic cancer with high market potential, and multiple shots on goal with major cancer research centers. Additionally, the current valuation is attractive, and further positive data from clinical trials could act as a catalyst for the stock. Potential risks include balance sheet and liquidity risks and failure to obtain regulatory approvals or suitable reimbursement.

Bears say

AIM ImmunoTech is focused on the development of Ampligen, a promising double-stranded RNA molecule with potential applications in multiple cancers, viral diseases, and immune-related disorders. The ongoing DURIPANC clinical trial, in collaboration with AstraZeneca and Erasmus MC, holds promising potential for the treatment of metastatic pancreatic cancer. With strong upcoming catalysts expected over the next year, AIM ImmunoTech could see significant growth and success in the near future.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.